Amgen er en hjørnesteinsbiotek-aksje som representerer en av industriens mest vellykkede selskaper, med en dypt rørledning av biologiske terapeier, en beviste merittliste for å bringe innovative medisiner på markedet, og skalaen til å investere milliarder årlig i forskning og utvikling på tvers av flere terapeutiske områder.
Amgen utvikler MariTide, en lovende neste generasjons fedmesykdom-stoffkandidat som kunne konkurrere på det raskt voksende markedet for vekttap-terapi ved siden av Eli Lilly og Novo Nordisk.
Data updated Feb 15 · Source: Twelve Data
Amgen is one of the world's largest and most established biotechnology companies, offering investors a rare combination of biotech innovation with large-cap stability. The stock has shown impressive momentum, up 25.5% over 90 days and trading near its 52-week high, well above its 50-day moving average of $338. At a P/E of 22.0 with EPS of $16.76, the valuation is reasonable for a diversified biotech of this caliber. Amgen's deep pipeline, anchored by blockbusters like Repatha and Prolia, provides durable revenue streams. The company's entry into the weight loss space with MariTide (AMG 133), a novel bispecific antibody targeting GIP/GLP-1 receptors, represents a significant growth catalyst, though it remains in mid-stage trials and faces stiff competition from Eli Lilly and Novo Nordisk. Bull case: diversified portfolio, strong cash flows, promising obesity pipeline, and shareholder-friendly capital returns. Bear case: patent cliffs on legacy drugs, high debt levels from the Horizon Therapeutics acquisition, and execution risk in the crowded obesity market. A solid core biotech holding with meaningful optionality.
Amgen (AMGN) stands as a titan in the biotechnology sector, offering a rare blend of blue-chip stability and high-growth potential. Trading near its 52-week high with a P/E ratio of 21.39, the valuation reflects market optimism surrounding its pipeline, particularly its entry into the lucrative obesity drug market with MariTide. The recent acquisition of Horizon Therapeutics further diversifies its revenue streams beyond legacy blockbusters. Unlike many volatile biotech peers, Amgen provides significant financial health and reliable cash flows, supporting a consistent dividend. However, risks remain regarding patent cliffs for aging drugs like Enbrel and the fierce competition within the GLP-1 weight-loss space. For investors looking for exposure to biotech innovation without the extreme volatility of clinical-stage companies, Amgen represents a robust, albeit fully valued, long-term hold.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
Hver trader har en strategi som ser flott ut i hodet deres. Backtesting er hvordan du finner ut om den faktisk fungerer. Her er hvordan du tester strategier på riktig måte, hvilke beregninger som betyr noe, og hvorfor de fleste backtestresultater er for gode til å være sant.
Powered by Rexiew